Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
Novavax' vaccine has received authorizations of the vaccine in over 170 countries
PeproTech's recombinant proteins portfolio complements Thermo Fisher's cell culture media products
Biogen paid Ionis a US $ 60 million one-time upfront payment
The latest research results indicated that JMB2002 had high binding activity to the Omicron variant and showed potent Omicron pseudovirus neutralization function
The first pilot study from India analyzing Covaxin-Covishield mixed doses
Partnering to build biosynthesis processes and a pharmaceutical production platform
Emergency Use Authorisation application request to be submitted following one month required by FDA EUA guidance
Oravax's oral VLP vaccine in development targets three SARS CoV-2 virus surface proteins, including proteins less susceptible to mutation, thus making the vaccine potentially more effective against current and future variants of the Covid-19 virus
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
Subscribe To Our Newsletter & Stay Updated
